Business Context and Reporting Period
Company: Organogenesis Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 1, 2023
Reporting Period: Fiscal fourth quarter and full year ended December 31, 2022.
This filing serves to announce the release of financial results for the specified period via a press release incorporated by reference as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the press release (Exhibit 99.1) referenced in the filing but are not included in the text of the 8-K itself.
Material Changes
The filing text does not provide specific data regarding material changes versus prior comparable periods. It only confirms the announcement of results for the fourth quarter and full year 2022.
Guidance, Outlook, and Risks
Management Commentary: The filing notes that the Company announced its results via press release on March 1, 2023.
Legal Status of Information: The information in the attached press release is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference in other filings except as expressly set forth.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific revenue, net income, and cash flow figures.
- Verify year-over-year growth rates and margin trends not detailed in this summary.
- Check for any forward-looking guidance or updated financial outlook provided in the press release.
- Confirm the status of the company's liquidity and debt obligations as of December 31, 2022.